2D Perovskite Nanosheet-Based Drug-Delivery Platform for Cancer Therapy – AZoM

The latest research in the Chemical Engineering Journal focuses on a sophisticated two-dimensional (2D) photonic drug-delivery technology based on PEGylated WO2.9 nanosheets (a substoichiometric version of WO3) (NSs).

Study:Oxygen-deficient tungsten oxide perovskite nanosheets-based photonic nanomedicine for cancer theranostics.Image Credit: Love Employee/Shutterstock.com

Photothermal therapy (PTT), a non-invasive technique of tumor treatment that employs photothermal agents (PTAs) to create local hyperthermia using near-infrared (NIR) laser light, has been extensively researched and has garnered considerable focus.

Perovskite nanosheets offer several appealing traits as 2D nanomaterials, including surface area features, mechanical flexibility, strong light-matter interaction, minimal trap-state density, and higher adsorption efficacy. Some perovskite nanosheets exhibit high photoluminescence.

However, because of the restricted tissue depth of penetration of the typical NIR-I bio-window (650950 nm), most PTT mediated by NIR-I is still insufficient for the effective treatment of big or severe tumors, contributing to an elevated remnant and recurrence rate.

In comparison, the NIR-II (10001700 nm) bio-window had a higher maximum permitted exposure (MPR), decreased photon scattering, increased penetration depth, and reduced tissue background, allowing NIR-II PTT to significantly enhance tumor treatment efficiency. Unfortunately, in comparison to the PTA active in the NIR-I region, the advancement of NIR-II materials is still behind.

The materials used by the researchers for the experiment included Sodium tungstate monohydrate (Na2WO4H2O), nitric acid (HNO3), chloroform (CHCl3) sodium borohydride (NaHB4), doxorubicin hydrochloride (DOX), calcein-AM, Propidium Iodide (PI), 4,6-diamidino-2- phenylindole (DAPI), and CCK-8.

Phosphate-buffered saline (PBS) (pH 7.4), cell culture medium, fetal bovine serum (FBS), penicillin-streptomycin, and trypsin-EDTA were also utilized during the research study.

Transmission electron microscopy, scanning electron microscopy, and atomic force microscopy was utilized for the research study.

First, 200 mg of Na2WO4H2O were scattered in 300 mL of HNO3 solution (5 M). The combined mixture was then swirled for three days at room temperature (RT) for bulk production of WO3H2O. Two rectangle porcelain crucibles with a volume of 5.0 cm 2.0 cm 1.5 cm were used. Firstly, 10 mg of WO3H2O NSs was placed in one of them, NaBH4 (5 mg) was placed in the other one. Two porcelain crucibles were then placed in a tubular furnace, and the porcelain crucibles containing WO3H2O NSs were held on top of the other with a rotation angle of 20.

To make PEG-coated WO2.9 NSs, WO2.9 NSs (10 mg) were combined with 25 mg DSPE-PEG dissolved in CHCl3 solution in 30 mL CHCl3 solution. The CHCl3 solution was removed using vacuum rotary evaporation after 30 minutes of ultrasonic treatment.

Different concentrations of DOX were dissolved in PBS solution (pH 7.4, 10 mM) and further mixed with [emailprotected]2.9 NSs. The final concentration of DOX was 0.2, 0.4, 0.6, 0.8 and 1 mg mL 1, respectively.

In the DMEM medium, 4 T1 cells, HUVEC cells, NCM-460 cells, and Hela cells were incubated. FBS (10%) and streptomycin/penicillin (1%) supplements were administered to all of the DMEM media for the generation of cell cultures.

The latest study showed that WO3H2O NS exhibited the typical Raman-active peaks at 120, 267, 326, 684, 810, and 960 cm 1. The PEGylated WO2.9 NS ([emailprotected]2.9 NS) still retained good dispersity and stability in the PBS and medium even after 24 h incubation, indicating that the dispersity and stability are significantly bet.

When the quantity of [emailprotected]2.9 NSs was 200 mg mL 1, the greatest temperature generated by 2.0 Wcm2 NIR-I irradiation was only 32.2 C. Under 808 nm and 1064 nm irradiation, the photothermal conversion efficiency of [emailprotected]2.9 NSs is determined to be 18.7 percent and 36.2 percent, respectively. These findings imply [emailprotected] NSs have a high potential for use as a photothermal agent for PTT against tumors in the NIR-II window.

The medication loading capacity of [emailprotected] NSs was then examined using a UVvis absorption spectrum. The concentration of DOX loaded onto [emailprotected] increased with the addition of the concentration of DOX, and the maximum drug load efficiency was approximately 102 percent at our studied parameters, which is significantly higher than most nanoparticle-based delivery platforms with drug-loading capacities of 10%30%.

In all cases, four T1 cells were co-cultured. There was no evident cytotoxicity in the groups that simply received NIR-II or [emailprotected]2.9 therapy. Hence, both nontoxicity and biocompatibility were confirmed.

Keeping in view the incredible findings, the WO2.9-based nanoplatform may open the way for a novel method to use more effective perovskite theragnostic nanomedicines for the cure of diverse solid cancers.

In short, 2D perovskite nanosheet drug delivery has been proved to be not only biocompatible but also quite effective for cancer treatment, revolutionizing biomedical applications of such materials and improving the health care treatment quality for people.

Zhang, L., Zhao, S., Ouyang, J., Deng, L., & Liu, Y. N. (2021). Oxygen-deficient tungsten oxide perovskite nanosheets-based photonic nanomedicine for cancer theranostics. Chemical Engineering Journal.https://www.sciencedirect.com/science/article/pii/S1385894721048488

Disclaimer: The views expressed here are those of the author expressed in their private capacity and do not necessarily represent the views of AZoM.com Limited T/A AZoNetwork the owner and operator of this website. This disclaimer forms part of the Terms and conditions of use of this website.


2D Perovskite Nanosheet-Based Drug-Delivery Platform for Cancer Therapy - AZoM

Nanofabrication: Techniques and Industrial Applications – AZoNano

As a bridge between fundamental research and the industrial application of nanotechnology, nanofabrication methods are essential in creating novel nanoscale structures, devices, and materials with unique properties. This article aims to overview the existing and emerging techniques for scalable, reliable, and cost-effective manufacturing at the nanoscale.

Image Credit:Macrovector/Shutterstock.com

Nanotechnology enables the understanding and control of matter at length scales between one and a few hundred nanometers, where the quantum effects dominate the properties of the materials.

The use of nanoscale materials has started quite early in human history and dramatically increased in the last 100 years. The study of small nanoparticles was pioneered by Richard Zsigmondy, an Austro-Hungarian colloid chemist, who was awarded the 1925 Nobel Prize in Chemistry. He used the term 'nanomatter' when characterizing particles such as gold colloids by using a microscope.

In 1959, Richard Feynman introduced the idea of manipulating matter at the atomic level. The future Nobel Laureate (he was awarded the 1965 Nobel Prize in Physics) presented a lecture at a meeting of the American Physical Society, where he speculated about miniaturized electronic components, atom-by-atom manufacturing, and novel optoelectronic and photonic technologies.

Feynman, who foresaw many aspects of modern nanoscience, together with K. Eric Drexler, who in 1986 hypothesized on how molecules and atoms can be manipulated and assembled into complex nanostructures, are considered the fathers of modern nanotechnology.

Since then, nanotechnology has become the foundation for many remarkable applications leading to exponential growth in almost every industrial sector. In the last three decades, rapid developments in physics, chemistry, engineering, and material science manipulated individual molecules and atoms' reality, thus enabling various manufacturing processes at the nanoscale, usually referred to as nanofabrication.

Nanofabrication can be defined as a process of assembling one-, two- or three-dimensional structures at the scale of 1-100 nm with a high degree of functionality and structural complexity. There are different methods for creating functional nanostructures that can be divided into top-down and bottom-up approaches.

In the top-down approach, the starting material is reshaped into the desired smaller structures by using physical or chemical processes, such as electron or ion beam milling, laser ablation, and reactive ion etching, that remove excess material until the final structure is obtained.

In contrast, bottom-up nanofabrication relies on the formation of nanostructures from individual atoms and molecules. Processes include chemical and physical vapor deposition (CVD and PVD), self-assembly, and epitaxial growth.

The Lurie Nanofabrication Facility at the University of MichiganPlay

Video Credit:Electrical and Computer Engineering at Michigan/YouTube.com

The majority of the industrial nanofabrication processes employ a combination of the two approaches and can be loosely divided into three major sub-processes: thin film deposition, lithographic patterning, and chemical or physical etching.

Thin films are layers of polymers, metals, semiconductors, or other functional materials with nanometer-level thickness. They are fabricated using a variety of deposition processes, including CVD, PVD, atomic layer deposition, and molecular beam epitaxy.

The lithography process involves patterning the as-deposited thin films to create integrated circuits or nanoelectromechanical systems. The latest generation of optical nanolithographic systems employs X-ray, extreme UV, or charged particles beams to create nanoscale patterns with a spatial resolution of less than 10 nm.

The pattern transfer is finalized by an etching process that selectively removes the unnecessary parts of the thin film

Such a combination of top-down and bottom-up methods, for example, underpins the tremendous advances in microelectronics and over the last 30 years.

With the development of the UV and extreme UV nanofabrication processes that permit the creation of structures smaller than 10 nm, the semiconductor industry has been able to continuously increase the integration density of the electronic circuits.

The technological developments behind the large-scale production of advanced integrated circuits, in turn, enabled the transfer of cost-effective nanofabrication techniques to the fields of telecommunications, optoelectronics, and photonics.

Nanomanufacturing can also help create materials with novel properties. With the discovery of nanomaterials like fullerenes, carbon nanotubes, graphene, nanodots, and metallic nanoparticles, a lot of academic and industrial research and development efforts were directed at incorporating such nanomaterials in the manufacturing of advanced construction materials, consumer goods, textiles, and healthcare products.

Surface nanopatterning (to create superhydrophobic surfaces) together with metallic nanoparticle coatings are used in antimicrobial applications. Building materials benefit from nanostructured coatings that enable self-cleaning and antifouling functionality.

Automotive and aerospace industries utilize metal oxide nanoparticles for temperature and corrosion protection, and carbon nanotube-based nanocomposite materials as high-strength structural materials.

Image Credit:Ico Maker/Shutterstock.com

The so-called 'soft nanotechnology', based on the self-assembly of large organic molecules (polymers and proteins), is an emerging field with rapidly expanding industrial applications.

The concept of using cheap and sustainable biobased resources to fabricate organic nanostructures is particularly attractive in the context of a circular economy. Nanoscale biomolecular structures are used for targeted drug delivery, rapid testing, high-throughput gene sequencing, and vaccines' latest generation.

Researchers are exploring ways to mimic photosynthesis, a complex interplay of molecular self-assembly and quantum mechanics, to create novel energy harvesting devices with nearly 100% quantum efficiency.

With the rapidly expanding applications of nanotechnology in the industry, there is a growing need for more versatile, scalable, and sustainable nanofabrication methods. An exciting perspective is the ability to create dynamical nanoscale structures capable of exhibiting a much broader range of functionalities.

To achieve this, scientists are learning from complex biological systems to take advantage of the engineering principles that drive nature's molecular machines.

Continue reading: An In-Depth Look at Top Down Nanofabrication.

Subhan, M.A., et al. (2021) Advances with Molecular Nanomaterials in Industrial Manufacturing Applications. Nanomanufacturing 1, 75-97. Available at: https://doi.org/10.3390/nanomanufacturing1020008

Nasrollahzadeh, M., et al. (2019) An Introduction to Nanotechnology. Interface Science and Technology, 28, 1-27. Available at: https://doi.org/10.1016/B978-0-12-813586-0.00001-8

Bayda, S., et al. (2019) The History of Nanoscience and Nanotechnology: From Chemical-Physical Applications to Nanomedicine. Molecules, 25(1), 112. Available at: https://dx.doi.org/10.3390%2Fmolecules25010112

Singh, N.A. (2017) Nanotechnology innovations, industrial applications and patents. Environ Chem Lett 15, 185191. Available at: https://doi.org/10.1007/s10311-017-0612-8

Disclaimer: The views expressed here are those of the author expressed in their private capacity and do not necessarily represent the views of AZoM.com Limited T/A AZoNetwork the owner and operator of this website. This disclaimer forms part of the Terms and conditions of use of this website.

Read more here:

Nanofabrication: Techniques and Industrial Applications - AZoNano

Nano-hinges are the next step in development of molecular machines – Innovation Origins

Scientists from Finland and Israel have found a way to enable nano-scaled hinges to move. This marks the next step in the development of what are known as molecular machines. This will ultimately make it possible to develop new therapeutic approaches in e.g. medicine.

Until now it has not been possible to control these kinds of nanomachines. The team of researchers from Aalto University in Finland and the Weizmann Institute in Israel have succeeded in creating a structure that opens and closes like a hinge on command. Its a bit like origami, that Japanese art of folding, according to the researchers.

In order to be able to build such a hinge, the scientists opted for the use of DNA. DNA not only carries genetic codes, but can also take on many different forms: the nano-hinges are contained in a solution that becomes more acidic when light shines on it. The increasing acidity of the solution causes chemical bonds to form in the ends of the hinges thereby closing the hinges, says Finnish scientist Joonas Ryssy. When the light is turned off, the acidity of the solution is reversed, causing the bonds between the ends to break and the hinges to open again. Only one light source is needed for that switching.

The results were published in the professional journal Angewandte Chemie. The research is a follow-up of earlier studies by the same group on the manipulation of macromolecules. The use of light to control the hinge is an attractive option because it can be done remotely.

Anton Kuzyk, professor at Aalto University: If we dont want all the hinges to close, we reduce the amount of light. This level of control is an exciting feature of our system that sets it apart from others.

Read other IO articles on nanotechnology here.

Read more here:

Nano-hinges are the next step in development of molecular machines - Innovation Origins

How hacked is hacked? Heres a hack scale to better understand the SolarWinds cyberattacks – GeekWire

(BigStock Photo)

Microsoft, FireEye, and the U.S. Treasury department have been hacked in the SolarWinds attacks.

This statement is true but doesnt tell the whole story accurately.

Its true because by most peoples understanding, these organizations have been hacked. But it doesnt tell the whole story accurately because each of these organizations has had different impacts with different levels of severity from the hack.

A good example of why this matters is how we talk about cancer. Years ago having cancer was a binary thing, too. Either you had cancer and were going to die or you didnt. And cancer was often talked about in hushed tones with euphemistic terms the C word.

Because of advances in medicine, this is no longer the case: people can and do survive cancer. So now we talk about cancer more openly in a way that reflects that reality in terms of types of cancer and stages. That helps us understand if its a kind of cancer that could be treatable and survivable or one that is untreatable and terminal.

The same is true now about being hacked. Some hacking is catastrophic, but some is survivable. We see this reality in the different reports coming out about SolarWinds hacks. Some organizations are severely affected while others less so. But these crucial nuances are lost when we say theyve all been hacked.

There is no hacked scale that is used by professionals, let alone that can be used by laypeople. This is one reason why we continue to just hear about hacked.

If were going to understand the nuances in the SolarWinds cases better, we need to define a scale. Since the most important thing in hacks is the spread and severity, the cancer staging system gives a good model to adapt because it tracks the spread and severity of cancer in five stages. We can do the same with hacks.

The key factors in these levels are the attackers access and control: less of each is better, more is worse.

For instance, SolarWinds has said that 18,000 customers were impacted. But this doesnt mean that 18,000 customers networks experienced Stage IV and are fully and totally controlled by the attackers.

The information SolarWinds provides only tells us that those customers experienced Stage 0: the attackers may have had a way to get further into the network. To know if attackers did go further and customers were more severely affected requires more investigation.

On Dec. 17, Microsoft said it can confirm that we detected malicious Solar Winds binaries in our environment, which we isolated and removed we have not found evidence of access to production services or customer data. Our investigations, which are ongoing, have found absolutely no indications that our systems were used to attack others. Taking the information at face value, that would seem to indicate that Microsoft experienced Stage 0 or Stage I.

FireEye made a disclosure on Dec. 8 of its own compromise that would turn out to be part of the SolarWinds attacks. It seems to indicate that the attacker was able to steal information but gave no indication that the attackers were able to alter data or gain administrative control of the network, likely making what the company experienced a Stage II.

Details of the U.S. Treasurys attack arent as clear in part because we only have the information second and third-hand. The information in the New York Times report clearly indicates that the attackers at least had read access on the network, which is consistent with Stage II. However, some of the details that have emerged about how the attackers may have gained access to cloud properties imply the possibility that the attackers had achieved Stage IV on the network.

The goal with any scale is to make things simple but not simplistic. But no scale is ever perfect; there are always going to be ways that scales can obscure critical details. The important thing with scales like this is to enable us to easily and succinctly understand the relative comparative severity of the situation. What we know does indicate that the Treasury situation is worse than the Microsoft or FireEye situations in this regard, this scale is accurate and useful.

The key point for everyone now is to understand that hacked isnt a simple binary state: there are different degrees of it. By understanding this we can better assess how serious a situation is and what we need to do in response.

The rest is here:

How hacked is hacked? Heres a hack scale to better understand the SolarWinds cyberattacks - GeekWire

Nanomedicine Market Forecast Estimation & Approach 2020-2026 | GE Healthcare, Johnson & Johnson, Mallinckrodt plc, Merck & Co. Inc.,…

The Global Nanomedicine Market report provides information by Top Players, Geography, End users, Applications, Competitor analysis, Sales, Revenue, Price, Gross Margin, Market Share, Import-Export, Trends and Forecast.

Initially, the report provides a basic overview of the industry including definitions, classifications, applications, and industry chain structure. The Nanomedicine market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status.

To Get Copy of Sample Report Kindly Connect with us https://www.affluencemarketreports.com/industry-analysis/request-sample/894345/

2020 Global Nanomedicine Market Report is a professional and in-depth research report on the worlds major regional market conditions of the Nanomedicine industry, focusing on the main regions and the main countries (United States, Europe, Japan and China).

Global Nanomedicine market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer.

The Top players are

Nanomedicine Market Report based on Product Type:

Nanomedicine Market Report based on Applications:

Get Extra Discount on Nanomedicine Market Report, If your Company is Listed in Above Key Players List @ https://www.affluencemarketreports.com/industry-analysis/request-discount/894345/

The report introduces Nanomedicine basic information including definition, classification, application, industry chain structure, industry overview, policy analysis, and news analysis. Insightful predictions for the Nanomedicine market for the coming few years have also been included in the report.

The report focuses on global major leading Nanomedicine Market players providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out.

The Nanomedicine industry development trends and marketing channels are analyzed. Finally, the feasibility of new investment projects is assessed, and overall research conclusions offered.

ENQUIRE MORE ABOUT THIS REPORT @ https://www.affluencemarketreports.com/industry-analysis/request-inquiry/894345/


Chapter 1: Nanomedicine Market Overview, Product Overview, Market Segmentation, Market Overview of Regions, Market Dynamics, Limitations, Opportunities and Industry News and Policies.

Chapter 2: Nanomedicine Industry Chain Analysis, Upstream Raw Material Suppliers, Major Players, Production Process Analysis, Cost Analysis, Market Channels and Major Downstream Buyers.

Chapter 3: Value Analysis, Production, Growth Rate and Price Analysis by Type of Nanomedicine.

Chapter 4: Downstream Characteristics, Consumption and Market Share by Application of Nanomedicine.

Chapter 5: Production Volume, Price, Gross Margin, and Revenue ($) of Nanomedicine by Regions (2014-2020).

Chapter 6: Nanomedicine Production, Consumption, Export and Import by Regions (2014-2020).

Chapter 7: Nanomedicine Market Status and SWOT Analysis by Regions.

Chapter 8: Competitive Landscape, Product Introduction, Company Profiles, Market Distribution Status by Players of Nanomedicine.

Chapter 9: Nanomedicine Market Analysis and Forecast by Type and Application (2020-2026).

Chapter 10: Market Analysis and Forecast by Regions (2020-2026).

Chapter 11: Industry Characteristics, Key Factors, New Entrants SWOT Analysis, Investment Feasibility Analysis.

Chapter 12: Market Conclusion of the Whole Report.

Chapter 13: Appendix Such as Methodology and Data Resources of This Research.

For More Details on Impact of COVID-19 on Nanomedicine Market https://www.affluencemarketreports.com/industry-analysis/covid19-request/894345/

About Affluence:

Affluence Market Reports is the next generation of all your research needs with a strong grapple on the worldwide market for industries, organizations, and governments. Our aim is to deliver exemplary reports that meet the definite needs of clients, which offers an adequate business technique, planning, and competitive landscape for new and existing industries that will develop your business needs.

We provide a premium in-depth statistical approach, a 360-degree market view that includes detailed segmentation, key trends, strategic recommendations, growth figures, Cost Analysis, new progress, evolving technologies, and forecasts by authentic agencies.

For more Details Contact Us:

Affluence Market Reports

Contact Person: Mr. Rohit

Phone Number: U.S +1-(424) 256-1722

Email: [emailprotected]

Website: http://www.affluencemarketreports.com


Nanomedicine Market Forecast Estimation & Approach 2020-2026 | GE Healthcare, Johnson & Johnson, Mallinckrodt plc, Merck & Co. Inc.,...

Nanomedicine Market With Size, Status, Demand, Current And Future Investments Forecast Till 2026: GE Healthcare, Johnson & Johnson, Mallinckrodt…

WMR added the Most up-to-date research on Nanomedicine Market Forecast to 2026 to its huge collection of research reports database. An insight into the important factors and trends influencing the market competition and opportunities in Investment. This Report compiled byWorldwide Market Reports features a succinct analysis of the latest market trends.

Nanomedicine market reports provide a comprehensive overview of the global market size and share. Nanomedicine market data reports also provide a 5 year pre-historic and forecast for the sector and include data on socio-economic data of global. Key stakeholders can consider statistics, tables & figures mentioned in this report for strategic planning which leads to the success of the organization.

Request a sample copy at: https://www.worldwidemarketreports.com/sample/205987

New business opportunities and rising demand for Nanomedicine market activates are the primary factors expected to drive the growth of the Nanomedicine market in the United States, EU, Japan, China, India, Africa, Southeast Asia are the major region leading the Nanomedicine market.

The major players profiled in this report include

Impact of COVID-19:

Nanomedicine Market report analyses the impact of Coronavirus (COVID-19) on the Nanomedicine industry. Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 180+ countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Nanomedicine market in 2020.

COVID-19 can affect the global economy in 3 main ways: by directly affecting production and demand, by creating supply chain and market disturbance, and by its financial impact on firms and financial markets.

Further in the Nanomedicine Market research reports, following points are included along with in-depth study of each point:

Production Analysis: Production of the Nanomedicine is analyzed with respect to different regions, types, and applications. Here, price analysis of various Nanomedicine Market key players is also covered.

Supply and Consumption: In continuation with sales, this section studies supply and consumption for the Nanomedicine Market. This part also sheds light on the gap between supply and consumption. Import and export figures are also given in this report.

Key Strategic Developments: The study also includes the key strategic developments of the Nanomedicine market, comprising R&D, new product launch, M&A, agreements, collaborations, partnerships, joint ventures, Global and regional growth of the leading competitors operating in the market on a global and regional scale.

Get Sample ToC to understand the CORONA Virus/COVID19 impact and be smart in redefining business strategies.https://www.worldwidemarketreports.com/covidimpact/205987

In this report, the global Nanomedicine market is valued at USD XX million in 2019 and is expected to reach USD XX million by the end of 2026, growing at a CAGR of XX% between 2019 and 2026.

The report provides an in-detail list of drivers and restraints in the market, which are influencing the market growth. Additionally, provides expected opportunities and emerging trends in the market.

The report includes a detailed study of Porters Five Forces model to analyze the different factors affecting the growth of the market. Moreover, the study also covers a market attractiveness analysis, PESTLE analysis, Value Chain Analysis, and SWOT analysis. The report also includes detailed abstracts about statistics, revenue forecasts, and market valuation, which additionally highlights its status in the competitive landscape and growth trends accepted by major industry players.

The report is a collection of first-hand information, qualitative assessment by industry analysts, and inputs from industry experts. Moreover, the report also maps the qualitative impact of various market factors on market segments and geographies. The major factor driving the adoption of Nanomedicine is the formation of a data encryption feature and data privacy feature. The major industry changing factors for the Nanomedicine market segments are explored in this report. This report also covers the growth factors of the global market based on end-users.

Benefits of Purchasing Nanomedicine Market Report:

Analyst Support: Get your query resolved from our expert analysts before and after purchasing the report.

Customers Satisfaction: Our expert team will assist with all your research needs and customize the report.

Inimitable Expertise: Analysts will provide deep insights into the reports.

Assured Quality: We focus on the quality and accuracy of the report.

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Nanomedicine market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares split, and breakdowns have been determined using secondary sources and verified primary sources.

*If you have any special requirements, please let us know and we will offer you the report as you want.

** The Values marked with XX is confidential data. To know more about CAGR figures fill in your information so that our business development executive can get in touch with you.

Place an Enquiry Before buying Nanomedicine Market Report 2026: https://www.worldwidemarketreports.com/quiry/205987

About WMR

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends.

See the original post here:

Nanomedicine Market With Size, Status, Demand, Current And Future Investments Forecast Till 2026: GE Healthcare, Johnson & Johnson, Mallinckrodt...

IKBFU Scientists Develop a Plant-Based Technology for Obtaining Magnetic Nanoparticles with Antifungal Properties – QS WOW News

A team of researchers from obtained magnetic nanoparticles using a sweet flag (Acorus calamus). Both the roots and the leaves of this plant have antioxidant, antimicrobial, and insecticide properties. The extract of the sweet flag was used as a non-toxic reagent for the manufacture of coated particles.

The authors of the work also showed the efficiency of the new nanoparticles against several types of pathogenic fungi that damage cultivated plants. A technology developed by the team provides for the manufacture of nanoparticles from a cheap plant-based raw material and reduces the harmful effect of reagents on the environment. The results of the study were publishedin theNano-Structures & Nano-Objectsjournal.

Because of their unique properties, nanoparticles are used in many areas, from medicine to oil production. Their characteristics depend to a great extent on their size and shape, and the ratio between their surface area and volume plays a key role. The bigger it is, the stronger is a nanoparticles local effect.

Magnetic nanoparticles that can be controlled with an external magnetic field or emit heat under the influence of electromagnetic radiation have potential in biology and medicine. For example, particles with increased magnetic moment are used both in medical diagnostics and for the treatment of various conditions. Some studies also indicate that magnetic nanoparticles can have antifungal properties. For these applications, scientists suggest using barium ferrite nanoparticles in the biocompatible coating.

There are several methods of manufacturing coated nanoparticles with given characteristics, but all of them include toxic reagents. We have developed an environmentally friendly technology for the production of barium ferrite with the use of sweet flag extract. The surface of these particles has additional biological properties and the particles themselves possess all necessary magnetic and geometrical characteristics, said Prof. Larissa Panina, a Ph.D. in Physics and Mathematics from BFU.

The team mixed an extract made from dried sweet flag roots with barium and iron salts and water. Then, the mixture was heated to evaporate the liquid and obtain powder. After that, the powder was sintered at temperatures up to 900C, and nanoparticles were formed.

To study their morphology, the team used scanning electron microscopy. This method is based on scanning the surface of a studied object with an electron beam and applies to fragments that are just several nanometers in size. The average size of the hexagon-shaped nanoparticles was from 20 to 50 nm. The team also studied the crystalline structure and elemental composition of the particles using X-ray structural analysis and energy dispersive spectroscopy and found out that the new particles had no admixtures.

The barium ferrite nanoparticles synthesized by the team were active against four species of fungi that cause various diseases of fruit and flowering plants. Even in small concentrations, the nanoparticles were able to slow down the growth of pathogens. In the course of the Fenton reaction, the ions of iron in barium ferrite reacted with peroxides and reactive oxygen forms (OH radicals) appeared.

Being extremely active, they reacted with substances in harmful cell walls, damaged them, and thus slowed down the growth of pathogens. According to the authors of the study, this is a universal mechanism that might make the nanoparticles active against other species of fungi, too.

Read the rest here:

IKBFU Scientists Develop a Plant-Based Technology for Obtaining Magnetic Nanoparticles with Antifungal Properties - QS WOW News

Antibacterial Nanorobots Market Improvement, Orientation and Forecast from 2020-2026| Bruker, JEOL, Thermo Fisher – Farming Sector

LOS ANGELES, United States: The report titled, Global Antibacterial Nanorobots Cartons Market Report, History and Forecast 2015-2026 has been recently published by QY Research. The authors of the report have done extensive study of the global Antibacterial Nanorobots Cartons market keeping in mind the key aspects such as growth determinants, opportunities, challenges, restraints, and market developments. This analysis will enrich the ability of the companies involved in the global Antibacterial Nanorobots Cartons market to make precise decisions. The report also emphasizes on the current and future trends in the global Antibacterial Nanorobots Cartons market, which may bode well for the global Antibacterial Nanorobots Cartons market in the coming years. Impact of the driving factors on the global Antibacterial Nanorobots Cartons market growth has been mapped by the report. Besides, factors that are likely to challenge the global Antibacterial Nanorobots Cartons market growth in the years to come are discussed by the industry experts in the report.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) https://www.qyresearch.com/sample-form/form/2217972/global-antibacterial-nanorobots-sales-market

The report thoroughly reviews the manufacturers operating in the global Antibacterial Nanorobots Cartons market. It offers figures pertaining to revenue, productions, and market share to provide a 360-degree view of it. They have used SWOT analysis to assess internal strengths, weaknesses, external opportunities, and threats. This is expected to help readers understand finer nuances of the market. This research report is presented in such a way that it helps a reader comprehend the market in wider aspects. In order to fulfil that goal, the researchers have divided the report into various chapters. It will provide readers with accurate and exact information, necessary for complete understanding of the market.

Key Players Mentioned in the Global Antibacterial Nanorobots Market Research Report: Bruker, JEOL, Thermo Fisher, Ginkgo Bioworks, Oxford Instruments, Imina Technologies, Toronto Nano Instrumentation, Klocke Nanotechnik, Kleindiek Nanotechnik, Park Systems

Global Antibacterial Nanorobots Market by Type: 50-100 nm, > 100nm

Global Antibacterial Nanorobots Market by Application: Nanomedicine, Biomedical Science

The researchers have covered the various product type, end user, and application segments in the Global Antibacterial Nanorobots Cartons Market Report. They have studied the varieties of products available in the market. Assessment of investments and innovation in these products has also been mentioned in complete detail. The application segment also receives spotlight through evaluation of possible usages of products.

The regions covered in the Antibacterial Nanorobots Cartons Market Report includes Asia Pacific, South Asia, the Middle East and Africa, North America, South America, and Europe. The research report analyses all the factors augmenting each regional market. It provides the historic, current, and forecast figures for them. Changing government policies and political volatility have been discussed at great length in this chapter to offer clarity.

Questions Answered by the Report:

Which are the dominant players of the global Antibacterial Nanorobots market?What will be the size of the global Antibacterial Nanorobots market in the coming years?Which segment will lead the global Antibacterial Nanorobots market?How will the market development trends change in the next five years?What is the nature of the competitive landscape of the global Antibacterial Nanorobots market?What are the go-to strategies adopted in the global Antibacterial Nanorobots market?

Request for customization in Report: https://www.qyresearch.com/customize-request/form/2217972/global-antibacterial-nanorobots-sales-market

Table of Contents

About Us:

QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), experts resources (included energy automotive chemical medical ICT consumer goods etc.

Follow this link:

Antibacterial Nanorobots Market Improvement, Orientation and Forecast from 2020-2026| Bruker, JEOL, Thermo Fisher - Farming Sector

These Nature-Inspired Solutions Could Be The Key To A More Sustainable Future – Tatler Philippines

By Relaxnews December 28, 2020

Climate change and biodiversity loss are laying bare our dependence on the natural world for everything from the food we eat to the air we breathe.

Sign up for our newsletters to get all our top stories delivered.

You've Successfully Subscribed

Climate change and biodiversity loss are laying bare our dependence on the natural world for everything from the food we eat to the air we breathe.

But nature also holds the solution to other problems, inspiring scientific discovery in a host of unexpected ways.

Nature is "a source of inspiration for science, because it has figured out the way Earth supports life," said Lex Amore from the Biomimicry Institute.

"It is imperative we look to the biological blueprints that have been successful over millennia to launch groundbreaking ideas faster."

From smelly durian fruit that could charge electric cars to sea sponges that might help build better spaceships, here is a selection of this year's scientific work inspired by nature.

Read also: What Is "Ecocide" And Should It Be A Crime?

Removing tumours and blood clots through minimal invasive surgery may soon become easier thanks to a flexible, ultra-thin and steerable needle inspired by parasitic wasps.

These formidable insects inject their eggs into living hosts such as caterpillars through a hollow needle called the ovipositor.

Scientists from the Delft University of Technology in the Netherlands studied the ovipositor's delivery mechanism, with blades that slide up and down alternately, using friction to push the eggs through.

Researchers designed a needle made up of sliding rods that imitate the ovipositor, according to a recent study in Frontiers in Bioengineering and Biotechnology.

They say the new needle is capable of reaching deeply buried parts of the body to inject medicine or remove harmful formations, while minimising trauma and patient recovery time.

This is a starkly different outcome than for the targets of parasitic wasps, whose larva often devour their caterpillar host from the inside.

Spiders make silk to entangle unsuspecting bugs, but now humans can use it to make optical lenses capable of picturing viruses that are invisible to the naked eye.

In a June study published in the Journal of Applied Physics, scientists said they used daddy-long-legs' dragline silk -- which makes a web's frame -- as a support for the lens.

In experiments, they covered a strand of spider silk in wax then dripped resin onto it. As it condensed, the silk naturally formed a dome, which researchers baked in an ultraviolet oven.

The resulting optical lens is about the size of a red blood cell and could be used to picture nano-scale objects like viruses or the insides of biological tissue.

As the lens is made from natural, non-toxic material, it can safely be used inside the body.

Read also: 3 Ways To Make Your Home Environmentally Sustainable

An intricately latticed marine sponge called the Venus' flower basket found in the depths of the Pacific Ocean could inspire stronger skyscrapers, longer bridges and lighter spacecraft, according to a September study published in Nature Materials.

Scientists discovered that the structure of the sponge's tubular skeleton gives it a higher strength-to-weight ratio than traditional designs that have been used for centuries for buildings and bridges.

"We've been studying structure-function relationships in sponge skeletal systems for more than 20 years, and these species continue to surprise us," said co-author James Weaver, a Harvard University scientist.

To some they are succulent and delicious, to others they are so overpoweringly stinky that they are routinely banned from hotel rooms across Southeast Asia.

But the durian fruit may be about to add a new unexpected reason for its fame -- helping to charge mobile phones and electric cars.

In a February study published in the Journal of Energy Storage, scientists described how they made extremely light and porous materials called aerogels from the fruit.

Aerogels are "great super-capacitors", which resemble energy reservoirs that dole out energy smoothly, said co-author and Sydney University associate professor Vincent Gomes.

"(Super-capacitors) can quickly store large amounts of energy within a small battery-sized device," he said.

They can then supply energy to charge electronic devices such as mobile phones, tablets and laptops within a few seconds, he added.

Read also: World Wildlife Fund PH: The New Normal Must Become A Green One

Cars, aeroplanes and buildings are mostly made of steel, concrete or brick.

Bamboo has attracted interest as a versatile construction material. But how to make it strong enough? In a May study published in the ACS Nano, researchers said they had found an answer.

By partially removing the lignin -- an organic substance which forms woody tissue -- and microwaving the bamboo, researchers said its strength nearly doubled.

Bamboo is already used to build houses and bridges, but this new discovery may further increase its popularity as a light, fast-growing and sustainable alternative to polluting materials.

From forests to the depths of the oceans, Amore from the Biomimicry Institute said there was "so much intelligence" to tap into in the natural world.

"We can use biomimicry, this practice of studying nature and replicating its strategies in design, to not only learn from nature's wisdom, but also heal ourselves -- and this planet -- in the process."

Originally posted here:

These Nature-Inspired Solutions Could Be The Key To A More Sustainable Future - Tatler Philippines

Targeted nanomedicines for the treatment of bone disease and regeneration – DocWire News

This article was originally published here

Med Res Rev. 2020 Dec 21. doi: 10.1002/med.21759. Online ahead of print.


Targeted delivery by either passive or active targeting of therapeutics to the bone is an attractive treatment for various bone related diseases such as osteoporosis, osteosarcoma, multiple myeloma, and metastatic bone tumors. Engineering novel drug delivery carriers can increase therapeutic efficacy and minimize the risk of side effects. Developmnet of nanocarrier delivery systems is an interesting field of ongoing studies with opportunities to provide more effective therapies. In addition, preclinical nanomedicine research can open new opportunities for preclinical bone-targeted drug delivery; nevertheless, further research is needed to progress these therapies towards clinical applications. In the present review, the latest advancements in targeting moieties and nanocarrier drug delivery systems for the treatment of bone diseases are summarized. We also review the regeneration capability and effective delivery of nanomedicines for orthopedic applications.

PMID:33347711 | DOI:10.1002/med.21759

The rest is here:

Targeted nanomedicines for the treatment of bone disease and regeneration - DocWire News

US Virtual 3D Nanorobots Market 2020: Deep Analysis of Current Trends and Future Demand by Top Key Players are Gingko Bioworks, Synthace, Zymergen…

Virtual 3D Nanorobots Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2020-2025Increasing prevalence of chronic diseases and rising adoption of technologically advanced medical equipments drive the growth of global virtual 3D nanorobots Market.

Get Sample Copy of The Activated Alumina Market Report 2020@ https://brandessenceresearch.com/requestSample/PostId/555

*The sample pages of this report is immediately accessible on-demand.**

Scope of Global Virtual 3D Nanorobots Market Report-

Nanorobots are nano electromechanical systems designed to perform a specific task with precision at nano scale dimensions. It will be mainly used for the treatment in field of nanomedicine. An interesting utilization of nanorobots may be their attachment to transmigrating inflammatory cells or WBC, to reach inflamed tissues and assist in their healing process. It can also used for biomedical instrumentation, early diagnosis and targeted drug delivery for cancer, pharmacokinetics, surgery, monitoring of diabetes and health care. Virtual 3D nanorobots are expected to provide personalized treatments with improved efficacy and reduced side effects that are not available today. Virtual 3D nanorobots can be used to treat genetic diseases by comparing the molecular structures of both DNA and proteins found in the cell to known or desired reference structures. Some of its potential applications are; early diagnosis and targeted drug delivery for cancer biomedical instrumentation, pharmacokinetics, monitoring of diabetes, surgery and others. Another possible application can be the capability to locate atherosclerotic lesions in stenosed blood vessels, particularly in the coronary circulation, and treat them either mechanically, chemically or pharmacologically.

Virtual 3D nanorobots marketreport is segmented on the basis of type, application, distribution channel and region & country level. Based upon type, global virtual 3D nanorobots market is classified into microbivore nanorobots, respirocyte nanorobots, clottocyte nanorobots. Based upon application, global virtual 3D nanorobots market is divided into dentistry, emerging drug delivery, brain aneurysm, cancer detection, gene therapy, nanomedicine, biomedical, healthcare and others.

The regions covered in this Virtual 3D Nanorobots Market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, the market of Virtual 3D Nanorobots is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, Middle East Asia (UAE, Saudi Arabia, Egypt) GCC, Africa, etc.

Some major key players for Global Virtual 3D Nanorobots Market Gingko Bioworks, Synthace, Zymergen Inc., Advanced Diamond Technologies and Advanced Nano Products Co. Limited and others.

Increasing Prevalence of Chronic Diseases and Rising Adoption of Technologically Advanced Medical Equipments Drive the Growth of Global Virtual 3D Nanorobots Market

Nanorobots are expected to provide new treatments for the patients suffering from different diseases. Latest developments in the field of biomolecular computing have demonstrated the feasibility of processing logic tasks by bio-computers. The major factor driving the growth of global virtual 3D nanorobots market is increasing adoption of technologically advanced products in healthcare coupled with the rising government initiatives in this field. In addition, increasing prevalence of chronic diseases, improving healthcare infrastructure and technological advancements to develop more innovative, better and effective medical treatments are also anticipated to foster the market growth within the forecast period. In recent years, the potential of nanotechnology motivated many governments to devote significant resources to this new field. The U.S. National Science Foundation launched a program in Scientific Visualization in part to harness supercomputers in picturing the nanoworld. Firms such as; IBM, PARC, Hewlett Packard, Bell Laboratories, and Intel Corp. and others are collaborating to produce new nano products.

Cancer can be successfully treated with current stages of medical technologies and therapy tools. One of the important aspect to achieve a successful treatment for cancer patients is the development of efficient targeted drug delivery to decrease the side effects from chemotherapy. Nanorobots can help on such extremely important aspects of cancer therapy owing to the properties of nanorobots to navigate as blood borne devices. Nanorobots with embedded chemical biosensors can be used to perform detection of tumour cells in early stages of development inside the patients body. Thus all these advantages of nanorobots are expected to boost the market growth.

However, lack of trained professional may hamper the market growth. In spite of that, increasing advancements in the field can provide various opportunities for the further growth of the market. The use of nanorobots may advance biomedical intervention with minimally invasive surgeries and help patients who need constant body functions monitoring, or ever improve treatments efficiency through early diagnosis of possible serious diseases.

North America is Expected to Dominate the Global Virtual 3D Nanorobots Market

The global virtual 3D nanorobots market is segmented into North America, Europe, Asia-Pacific Latin America and Middle East & Africa. North America is expected to dominate the global virtual 3D nanorobots market within the forecast period attributed to the highly developed healthcare infrastructure and increasing adoption of new technologies in healthcare in this region. In addition, increasing government initiative in this field are also supplementing the growth of virtual 3D nanorobots market in this region. Asia Pacific is anticipated to witness a significant growth in global Virtual 3D Nanorobots market owing to emerging economies and growing awareness about nanorobotics in healthcare. In addition, improving healthcare infrastructure due to the favourable government initiatives regarding health are also expected to foster the growth of virtual 3D nanorobots market in this region within the forecast period.

Key Benefits for Market Report

Virtual 3D Nanorobots MarketSegmentation:-

By Type: Respirocyte Nanorobots, Microbivore Nanorobots, Clottocyte Nanorobots

By Application:-Dentistry, Gene therapy, Brain Aneurysm, Emerging Drug Delivery, Cancer detection, NanoMedicine, Biomedical, Healthcare, Others

By Regional & Country Analysis

North America, US, Mexico, Chily, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, South Korea, Japan, India, Southeast Asia, Latin America, Brazil, The Middle East and Africa, GCC, Africa, Rest of Middle East and Africa

Get Full Report :@ https://brandessenceresearch.com/technology-and-media/virtual-d-nanorobots-market

Related Links : https://sites.google.com/view/industrytrends/healthcare-industry-trends/contract-research-organization-market-size-will-grow-at-a-cagr-of-7-4























About Us:

Brandessence Market Research and Consulting Pvt. ltd.

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Contact us at: +44-2038074155 or mail us atsales@industrystatsreport.com







Excerpt from:

US Virtual 3D Nanorobots Market 2020: Deep Analysis of Current Trends and Future Demand by Top Key Players are Gingko Bioworks, Synthace, Zymergen...

Healthcare Nanotechnology (Nanomedicine) Market : Updates, Future Growth, Industry Analysis And Comprehensive Study On Key Players To 2020 2028 -…

Healthcare Nanotechnology (Nanomedicine) Market is analyzed with industry experts in mind to maximize return on investment by providing clear information needed for informed business decisions. This research will help both established and new entrants to identify and analyze market needs, market size and competition. It explains the supply and demand situation, the competitive scenario, and the challenges for market growth, market opportunities and the threats faced by key players.

A 360 degree outline of the competitive scenario of the Global Healthcare Nanotechnology (Nanomedicine) Market is presented by Quince Market Insights. It has a massive data allied to the recent product and technological developments in the markets.

Sample Copy of This Report: https://www.quincemarketinsights.com/request-sample-64780?utm_source=biznews/ARSHAD

It has a wide-ranging analysis of the impact of these advancements on the markets future growth, wide-ranging analysis of these extensions on the markets future growth. The research report studies the market in a detailed manner by explaining the key facets of the market that are foreseeable to have a countable stimulus on its developing extrapolations over the forecast period.

Sanofi SA, Pfizer Inc., Celgene Corporation, Luminex Corporation, and Taiwan Liposome Company Ltd.

Reasons for buying this report:

By Application (Drug Delivery, Biomaterials, Active Implants, Diagnostic Imaging, Tissue Regeneration), By Disease (Cardiovascular Diseases, Oncological Diseases, Neurological Diseases, Orthopedic Diseases, Infectious Diseases and Other Diseases)

Healthcare Nanotechnology (Nanomedicine)

Get ToC for the overview of the premium report @ https://www.quincemarketinsights.com/request-toc-64780?utm_source=biznews/ARSHAD

A detailed outline of the Global Healthcare Nanotechnology (Nanomedicine) Market includes a comprehensive analysis of different verticals of businesses. North America, Latin America, Asia-Pacific, Africa, and Europe have been considered for the studies on the basis of several terminologies.

This is anticipated to drive the Global Healthcare Nanotechnology (Nanomedicine) Market over the forecast period. This research report covers the market landscape and its progress prospects in the near future. After studying key companies, the report focuses on the new entrants contributing to the growth of the market. Most companies in the Global Healthcare Nanotechnology (Nanomedicine) Market are currently adopting new technological trends in the market.

Finally, the researchers throw light on different ways to discover the strengths, weaknesses, opportunities, and threats affecting the growth of the Global Healthcare Nanotechnology (Nanomedicine) Market. The feasibility of the new report is also measured in this research report.

Table of Contents:


QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.


Quince Market Insights

Ajay D. (Knowledge Partner)

Office No- A109

Pune, Maharashtra 411028

Phone: APAC +91 706 672 4848 / US +1 208 405 2835 / UK +44 144 439 0986

Email: sales@quincemarketinsights.com

Web: https://www.quincemarketinsights.com

Follow this link:

Healthcare Nanotechnology (Nanomedicine) Market : Updates, Future Growth, Industry Analysis And Comprehensive Study On Key Players To 2020 2028 -...

Global Nanomedicine market 2020- Industry Overview, Global Trends, Market Analysis, CAGR Values and Country Level Demand To Forecast by 2027 -…

Global Nanomedicine market Industry Trends and Forecast to 2027 New Research Report Added to Databridgemarketresearch.com database. The report width Of pages : 350 Figures: 60 And Tables: 220 in it. To build an influential report, detailed market analysis has been conducted with the inputs from industry experts. By working on a number of steps for collecting and analysing market data, this supreme market research report is prepared with the expert team. It describes various definitions and segmentation or classifications of the industry, applications of the industry and value chain structure. Businesses can obtain a complete knowhow of general market conditions and tendencies with the information and data involved in the credible Global Nanomedicine market business report. The foremost areas of market analysis such as market definition, market segmentation, competitive analysis and research methodology are looked upon very vigilantly and precisely throughout the report.

Global nanomedicine market is registering a healthy CAGR of 15.50% in the forecast period of 2019-2026. This rise in the market value can be attributed to increasing number of applications and wide acceptance of the product globally. There is a significant rise in the number of researches done in this field which accelerate growth of nanomedicine market globally.

Get Sample Report + All Related Graphs & Charts @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-nanomedicine-market

Key Market Competitors

Few of the major market competitors currently working in the global nanomedicine market are Abbott, Invitae Corporation, General Electric Company, Leadiant Biosciences, Inc., Johnson & Johnson Services, Inc., Mallinckrodt, Merck Sharp & Dohme Corp., NanoSphere Health Sciences, Inc., Pfizer Inc., CELGENE CORPORATION, Teva Pharmaceutical Industries Ltd., Gilead Sciences, Inc., Amgen Inc., Bristol-Myers Squibb Company, AbbVie Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Luminex Corporation, Eli Lilly and Company, Nanobiotix, Sanofi, UCB S.A., Ablynx among others.

Competitive Landscape

Global nanomedicine market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of nanomedicine market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Key Insights in the report:

Complete and distinct analysis of the market drivers and restraints

Key Market players involved in this industry

Detailed analysis of the Market Segmentation

Competitive analysis of the key players involved

Market Drivers are Restraints

Grab Your Report at an Impressive 30% Discount! Please click Here @ https://www.databridgemarketresearch.com/request-a-discount/global-nanomedicine-market

Market Segmentation:-

By Product Type

By Application

By Indication

By Modality

To comprehend Global Nanomedicine market dynamics in the world mainly, the worldwide Nanomedicine market is analyzed across major global regions.

Actual Numbers & In-Depth Analysis, Business opportunities, Market Size Estimation Available in Full Report.

Some of the Major Highlights of TOC covers:

Chapter 1: Methodology & Scope

Definition and forecast parameters

Methodology and forecast parameters

Data Sources

Chapter 2: Executive Summary

Business trends

Regional trends

Product trends

End-use trends

Chapter 3: Industry Insights

Industry segmentation

Industry landscape

Vendor matrix

Technological and innovation landscape

For More Insights Get Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-nanomedicine-market

Nanomedicine Market report effectively provides required features of the global market for the population and for the business looking people for mergers & acquisitions, making investments, new vendors or concerned in searching for the appreciated global market research facilities. It offers sample on the size, offer, and development rate of the market. The Nanomedicine report provides the complete structure and fundamental overview of the industry market.

Note: If you have any special requirements, please let us know and we will offer you the report as you want.

About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.


Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email: Corporatesales@databridgemarketresearch.com

View post:

Global Nanomedicine market 2020- Industry Overview, Global Trends, Market Analysis, CAGR Values and Country Level Demand To Forecast by 2027 -...

ACED one year on: a promising first year for the early detection research alliance – Cancer Research UK

The International Alliance for Cancer Early Detection (ACED) is a 55 million ($70 million) partnership between Cancer Research UK (CRUK) and five of the worlds foremost centres in early detection research. One year on, we look at four recently awarded research projects, which show how the Alliance is building a scientifically diverse and collaborative research community in the UK and the US, united at the forefront of cancer early detection.

Detecting and diagnosing cancer early is complex and has been hindered by scientific and clinical challenges. With a fragmented research community, limited access to early-stage tissue samples and a lack of commitment or prioritisation from industry and research funders, research progress in this emerging field has been slow.

Founded in 2019, ACED is a CRUK partnership with the Canary Center at Stanford University, the University of Cambridge, the Knight Cancer Institute at Oregon Health and Science University (OHSU), University College London and the University of Manchester. The Alliance brings together leaders in early detection research in a collaborative community, to work together to generate novel ideas and share knowledge. Its research strategy spans the scientific pipeline; from understanding the fundamental biology of early stage disease to developing new technological approaches and implementing early detection strategies through clinical trials and health systems.

The five ACED Member Centres can access funding in three areas: core funding for building capacity; shared infrastructure funding for training, networking and research platforms/resources; and joint funding for collaborative research activities. In its first year, 14 research projects have been funded including 3 Project Awards, 9 Pilot Awards and 2 Skills Exchange and Development Travel Awards.

Project Award, led by: Georgios Lyratzopoulos, University College London; Antonis Antoniou, University of Cambridge; and Ruth Etzioni, Oregon Health and Science University

Currently, about 90% of cancer patients in England are diagnosed after symptom onset. Appropriately assessing the risk of undiagnosed cancer in patients who present with new symptoms is therefore critical for achieving earlier diagnosis. Yet our approach to classifying such risk is imperfect. Clinical guidelines do not encompass lower-risk symptoms, which are the presenting features of about half of all patients. Further, among patients who do present with high-risk symptoms mandating urgent referrals, only one in 12 are found to have cancer. In 2019, the last pre-pandemic year, about 2 million patients in England who were investigated urgently were found not to have cancer, and improvements in risk classification could allow NHS diagnostic services to be used more efficiently in the future.

To improve upon these two problems, and drawing on their statistical, computational and health informatics expertise and that of their collaborators, Georgios, Antonis and Ruth will utilise rich electronic health record data to develop algorithms to risk-stratify patients presenting with symptomatic-but-as-yet-undiagnosed cancer. In particular, they will aim to incorporate information on the patients medical history (with regard to diagnostic investigations, morbidities and past medications) into their algorithm, together with information on underlying susceptibility to cancer due to lifestyle-related exposures or genetic risk.

Beyond improving the assessment of cancer risk, this project will also facilitate future early detection research by delivering reproducible operational definitions (otherwise known as patient record phenotypes), that can be used by other members of the Alliance and the scientific community at large when using novel patient record datasets in the UK, the US and globally.

Project Award, led by: Marc Tischkowitz, University of Cambridge; Allison Kurian, Canary Center at Stanford for Cancer Early Detection; and Gareth Evans, University of Manchester

CanRisk is a validated cancer risk assessment tool which combines genetic, lifestyle, clinical and imaging data to calculate an individual risk estimate for women with high-risk mutations in BRCA1 and BRCA2. Currently the women who carry these mutations are given wide cancer risk estimates. For example, someone might be told they have a 5085% lifetime risk of developing breast cancer. But for that individual, they really want to know is it nearer to 50% or 85%, or perhaps even outside that range?

Now, with an ACED Project Award, Allison, Gareth and Marc are collaborating to determine how CanRisk can be best used in the clinic. The researchers will recruit patients via genetics clinics in the UK and US, randomising them between a personalised or conventional risk estimate group. They will follow patient uptake of cancer surveillance and risk-reducing mastectomy, as well as analysing psychological and economic measures. The international nature of this project, across three centres in two different countries, will enable the team to investigate the difference in early detection uptake across different health systems. Moreover, it will benefit the wider research community by establishing a risk-stratified cohort that could form the basis for further early detection studies in the future.

Pilot Award, led by: Alice Fan, Canary Center at Stanford for Cancer Early Detection; Emma Woodward, University of Manchester; and Eamonn Maher University of Cambridge

Platelet transcriptomes have the ability to respond to the presence of different cancer types by splicing RNA into specific patterns. Rapid platelet turnover and the ability to propagate this transcriptional response throughout the entire platelet population may prove to be a very sensitive biomarker for cancer.

Alices lab at Stanford has generated promising preliminary data for a candidate platelet transcriptomic signature for early-stage renal cell cancer. With this ACED Pilot Award, Emma, Eamonn and Alice will join forces to investigate if this signature can be used to complement diagnostic imaging for the early diagnosis of kidney cancer in high-risk families with hereditary renal cell carcinoma syndromes.

Skills Exchange and Development Travel Award, Christian Hoerner, Canary Center at Stanford for Cancer Early Detection

Isolating platelets from fresh whole blood for transcriptome profiling can be very tricky. Platelets activate very easily and contain only tiny amounts of RNA, 10,000 times less than white blood cells. Christian, a researcher in Alices lab, has been awarded a Skills Exchange and Development Travel Award to share his platelet isolation protocol with the Manchester and Cambridge teams. This award directly addresses a key aim of the ACED Alliance to drive the exchange of knowledge between teams and minimise duplication.

COVID-19 has undoubtedly had a significant impact on the first year of the ACED Alliance, delaying the start of many projects when labs were forced to shut, and clinicians redeployed to respond to the virus.

Alliance members have rapidly had to adapt the way they come together to create new collaborations and ideas. Planned in-person networking events were quickly reimagined as virtual ones and members have held numerous online meet-and-greet events on topics including model systems, epidemiological approaches, non-invasive sampling, nanomedicine and career development for early career researchers. We know of at least two successful grant applications that were brokered at virtual events, as researchers continue to build connections across multiple disciplines and centres.

As the Alliance develops, there will be many opportunities to work with us, including:

If you're interested in working with us, we'd love to hear from you.

By David Crosby, Head of Prevention and Early Detection Research, Cancer Research UK

Sanjiv Sam Gambhir, MD, PhD, professor and chair ofradiologyat theStanford School of Medicineand an internationally recognised pioneer in molecular imaging, died of cancer on 18 June 2020.

Sam was a giant in the field of early detection of cancer, well known for the development of positron emission tomography reporter genes. His work was novel and wide-reaching, developing multiple other approaches to early detection of disease, including microbubbles and immunodiagnostics. Through his work as director of the Canary Center at Stanford for Cancer Early Detection, he was a passionate advocate of devising ambitious plans to deliver paradigm-changing opportunities for early detection and a champion of ACEDs mission. He was a critical founding member of the Alliance Executive Board.

It is certainly the case that ACED would not exist without Sam. He was the inspiration that led directly to the concept of ACED, and only through his ingenuity and positivity did that concept develop into the flourishing reality that ACED now is. We, and the world, are greatly diminished for his loss.

Sam was posthumously given the Don Listwin Award for outstanding contribution to the field of cancer early detection at this years Early Detection of Cancer Conference. Before his death, Sam was also awarded the Deans Medal, the University of Stanford School of Medicines highest honour, for his revolutionary contributions to biomedicine and to human health. To find out more about Sams life and his legacy watch the Deans Medal Tribute video.

See more here:

ACED one year on: a promising first year for the early detection research alliance - Cancer Research UK

Growth Opportunities in Digital, Microbiome-based, and Preventive Healthcare Technologies, 2020 Report – Focus on Latest Advancements for Chronic Pain…

DUBLIN--(BUSINESS WIRE)--The "Growth Opportunities in Digital, Microbiome-based, and Preventive Healthcare Technologies 2020" report has been added to ResearchAndMarkets.com's offering.

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides insights across recent innovations in digital health, microbiome, and flu vaccines technologies. The TOE also provides insights across latest advancements for chronic pain management and COVID-19 testing.

The TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Key Topics Covered:

For more information about this report visit https://www.researchandmarkets.com/r/v6l8dq

Read the rest here:

Growth Opportunities in Digital, Microbiome-based, and Preventive Healthcare Technologies, 2020 Report - Focus on Latest Advancements for Chronic Pain...

NHMRC awards Griffith University $4.5 million in research funding – Griffith News

Key Griffith University research projects have received $4.5 million in funding from the National Health and Medical Research Council.

Announced on December 15 by the Federal Minister for Health, The Honorable Greg Hunt MP, the seven Ideas Grants projects will contribute to vital health and medical research.

Deputy Vice Chancellor (Research) Professor Mario Pinto said the funding highlights the extraordinary work conducted by the Universitys researchers in addressing major societal health challenges.

These projects have the potential to make a significant difference to peoples health and wellbeing. I extend my congratulations and appreciation to all staff who have contributed to these efforts.

More than half the funding for Griffith University was awarded to projects within theInstitute for Glycomics, withfour research projects securing $2.56 million to explore a super vaccine that tackles bothinfluenza virus andGroup A Streptococcus bacteria and other vaccine development projects that tackle other clinically important bacterial infections.

Institute Director Professor Mark von Itzstein AO said the awards cemented the Institutes reputation as a leading biomedical research institute.

Our institute is focussed on translational research outcomes that diagnose, prevent and treat diseases of global impact. These grants will significantly assist our researchers to deliver on our mission to achieve a disease-free world.


Dr Mehfuz Zaman, Professor Mark von Itzstein and Professor Michael Good (Institute for Glycomics) awarded $707, 717 for the project Vaccine to prevent Influenza Virus and Bacterial superinfection (Associate Professor Victor Huber, University of South Dakota).

Associate Professor Kate Seib, Professor Michael Jennings and Dr Arun Everest-Dass (Institute for Glycomics) awarded $826,490 for the project Gonococcal vaccine development guided by a cross-protective meningococcal vaccine (Dr Caroline Thng, Gold Coast Health).

Dr Freda Jen, Associate Professor Kate Seib, Professor Michael Jennings and Dr Milton Kiefel (Institute for Glycomics) awarded $526,949.6 for the project Targeting a bacterial glycol-Achilles heel to make new vaccines for Haemophilus influenzae and Neisseria gonorrhoeae.

Professor Michael Jennings, Associate Professor Thomas Haselhorst, Dr Lucy Shewell, Dr Christopher Day (Institute for Glycomics) awarded $608,425 for the project Structure and biophysical analysis aided design of novel toxoid vaccines for a major class of bacterial toxins (Prof James Paton, The University of Adelaide, Prof Mark Walker, The University of Queensland and Prof Victor Torres, New York University).

Dr David Lloyd, Dr Claudio Pizzolato, Dr David Saxby and Dr Laura Diamond (Menzies Health Institute Queensland) awarded $860, 231 for the project Osteoarthritis compass: Predicting personalized disease onset and progression with future capacity for clinical use (Dr Michelle Hall, Assoc Prof Adam Bryant University of Melbourne, Prof David Hunter, University of Sydney; Prof Juha Toyras, Dr Shekhar Chandra, Assoc Prof Craig Engstrom The University of Queensland; Dr Jurgen Fripp, CSIRO Australian e-Health Research Centre; Prof Rami Korhonen, University of Eastern Finland).

Professor Heidi Zeeman, Dr David Painter and Professor Elizabeth Kendall (Menzies Health Institute Queensland) awarded $513, 483 for the project Dimensional Attention Modelling for Neglect Detection (DIAMOND): A novel application for brain injury (Prof Julie Bernhardt, Florey Institute of Neuroscience and Mental Health).

Associate Professor Hang Ta (Queensland Micro and Nanotechnology Centre/GRIDD) awarded $523, 342 for the project Developing smart nanomedicine to enable advanced diagnosis and stimuli-responsive treatment for atherosclerosis and thrombosis (Dr Nghia Truong Phuoc, Monash University; Dr Gary Cowin, Dr Nyoman Kurniawan, Prof Zhiping Xu, The University of Queensland and Prof Karlheinz Peter, Baker Heart and Diabetes Institute).

Griffith researchers involved in research led by other institutions


Prof Randipsingh Bindra, Dr Mo Chen, Assoc Prof James St John, Assoc Prof Jenny Ekberg, Dr Brent McMonagle (Griffith Health) are part of a team led by Assoc Prof Jeremy Crook (University of Wollongong) awarded $805,064.45 for the project titled A wireless electric nerve-guide for peripheral nerve repair (Dr Eva Tomaskovic-Crook, University of Wollongong).

Assoc Prof Joshua Byrnes (MHIQ, Health) is part of a team led by Assoc Prof Maree Toombs (The University of Queensland) awarded $1,279,602.45 for the project titled Advancing equitable and non-discriminatory access to health services for First Nations peoples: A multidisciplinary Queensland Human Rights Act case study (Dr Shivashankar Hiriyur Nagaraj, Queensland University of Technology; Jodie Luck, Mr DanielWilliamson, Queensland Health; Mr Jed Fraser, Queensland Aboriginal and Islander Health Council; Prof Anthony Smith, Dr Claire Brolan Dr Caitlin Curtis, Dr Sandra Creamer, Prof Wendy Hoy, Dr Amelia Radke (The University of Queensland), Dr Kelly Dingli (Queensland Aboriginal and Islander Health Council); Mr Gregory Pratt (The Council of the Queensland Institute of Medical Research)

ARC Linkage 2020 Round 1

Dr Pooja Sawrikar (School of Human Services and Social Work) is part of a Western Sydney University project led by Assoc Prof Rebekah Grace awarded $387,107 for the project Upholding the right to cultural connection for children in care.


NHMRC awards Griffith University $4.5 million in research funding - Griffith News

Clene Nanomedicine Presents Blinded Interim Results from RESCUE-ALS Phase 2 Study at the 31st International Symposium on ALS/MNDResults provide…

SALT LAKE CITY, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, today announced the presentation of blinded interim results from the Phase 2 RESCUE-ALS clinical trial investigating the effects of its lead clinical candidate, CNM-Au8, for the treatment of amyotrophic lateral sclerosis (ALS). CNM-Au8 is an aqueous suspension of clean-surfaced, faceted gold nanocrystals with catalytic activity that has been shown to enhance the metabolic energetic capacity of motor neurons while simultaneouslyreducing oxidative stress.

As of the data cutoff (October 27, 2020), the trial was fully enrolled with a preliminary blinded assessment of the studys primary endpoint, the motor neuron number index-4 [MUNIX(4)] score, showing that more than 40% of enrolled patients with completed week 12 data experienced improvements in motor neuron function assessed by MUNIX. When compared to baseline values, the average MUNIX(4) score of the overall trial population (including both active CNM-Au8 and placebo) experienced an absolute increase in mean MUNIX(4) values. This increase exceeded the expectations of the statistical modeling on which the study was based, which predicted a linear decline in average MUNIX(4) score from study onset (Neuwirth et al. JNNP 2015). These data, while blinded, suggest that CNM-Au8 may have neuro-reparative potential in ALS patients. Clene expects to report the complete, unblinded results from the RESCUE-ALS study in 2H 2021.

Although blinded to treatment assignment, these data are encouraging. We believe Clenes breakthrough approach with the application of physics to biology via direct electron interactions within cellular systems at the nano-scale may hold the potential to revolutionize the treatment of neurodegenerative diseases such as ALS and other motor neuron diseases, said Robert Glanzman, MD, FAAN, Chief Medical Officer of Clene.

Rob Etherington, President and CEO of Clene added, This blinded interim analysis suggests that CNM-Au8 is working mechanistically to address a foundational challenge common to many neurodegenerative diseases, namely that stressed or failing neurons need additional energy for their survival, repair, and improved function. Emerging MUNIX data potentially indicate preservation of motor units, which is promising. We eagerly anticipate final results and are encouraged that these blinded interim results may provide hope for ALS patients and their families as they search for new therapies to treat this devastating disease.

The presentation (CLT-23) titled, RESCUE-ALS Trial, A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CNM-Au8 to Slow Disease Progression in Amyotrophic Lateral Sclerosis Patients: Design and Interim Blinded Results, is available as a live e-Poster on December 10th at 12:10 12:50 pm EST at the Virtual 31st International Symposium on ALS/MND, held online (https://symposium.mndassociation.org/virtual-2020/).

About RESCUE-ALSRESCUE-ALS is a Phase 2 multi-center, randomized, double-blind, parallel group, placebo-controlled study examining the efficacy, safety, pharmacokinetics and pharmacodynamics of CNM-Au8 in participants who are newly symptomatic with ALS (within 24-months of screening or 12-months from diagnosis). Enrolled subjects will be randomized 1:1 to receive either active treatment with CNM-Au8 (30 mg) or placebo in addition to their current standard of care. Participants will receive their randomized treatment over 36 consecutive weeks during the treatment period. The objective of this study is to assess the impact of improving neuronal bioenergetics, reducing reactive oxygen species and promoting protein homeostasis with CNM-Au8 to slow disease progression in patients with ALS. In the trial, efficacy is assessed as the average change in motor neuron unit number index (MUNIX) estimated by electromyography for the abductor digiti minimi (ADM), abductor pollicis brevis (APB), biceps brachii (BB), and tibialis anterior (TA) (muscles of the hand, arm, and leg). The trial was fully enrolled with 44 participants as of the reported 27-October-2020 data cut. Baseline characteristics include [mean (SD)], MUNIX(4) score: 93.7 (45.8); FVC % predicted: 80.8 (16.3); ALSFRS-R: 38.6 (6.1); ALSSQOL-20: 3.3 (1.3), mean time from diagnosis: 4.7 (4.6) months; riluzole background treatment, 92%.

About CNM-Au8CNM-Au8 is a concentrated, aqueous suspension of clean-surfaced faceted gold nanocrystals that act catalytically to support important intracellular biological reactions. CNM-Au8 consists solely of pure gold nanoparticles, composed of clean-surfaced, faceted, geometrical crystals held in suspension in sodium bicarbonate buffered, pharmaceutical grade water. CNM-Au8 has demonstrated safety in Phase 1 studies in healthy volunteers and has shown both remyelination and neuroprotective effects in multiple preclinical (animal) models. Preclinical data, both published in peer-reviewed journals and presented at scientific congresses, demonstrate that treatment of neuronal cultures with CNM-Au8 improves survival of neurons, protects neurite networks, decreases intracellular levels of reactive oxygen species and improves mitochondrial capacity in response to cellular stresses induced by multiple disease-relevant neurotoxins. Oral treatment with CNM-Au8 improved functional behaviors in rodent models of ALS, multiple sclerosis, and Parkinsons disease versus vehicle (placebo). CNM-Au8 is currently being tested in a Phase 2 clinical study for the treatment of chronic optic neuropathy in patients with MS in addition to Phase 2 and Phase 3 clinical studies for disease progression in patients with ALS.

About ALSALS is a universally fatal neurodegenerative disorder that results in loss of motor neurons in the cerebral cortex, brain stem, and spinal cord. ALS, also known as Lou Gehrig's disease, leads to the death of the neurons controlling voluntary muscles resulting in weakness, muscle atrophy, and progressive paralysis. ALS affects more than 15,000 patients in the United States and is the most prevalent adult-onset progressive motor neuron disease.

About CleneClene is a clinical-stage biopharmaceutical company focused on the development of unique therapeutics for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. Clene has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses. Founded in 2013, the company is based in Salt Lake City, Utah with R&D and manufacturing operations located in North East, Maryland. For more information, please visit http://www.clene.com.

Forward-Looking StatementsThis press release contains, and certain oral statements made by representatives of Tottenham, Clene, and their respective affiliates, from time to time may contain, "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Tottenham's and Clene's actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "might" and "continues," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, Tottenham's and Clene's expectations with respect to future performance and anticipated financial impacts of the business combination, the satisfaction of the closing conditions to the business combination and the timing of the completion of the business combination. These forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from expected results. Most of these factors are outside the control of Tottenham or Clene and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement relating to the proposed business combination; (2) the outcome of any legal proceedings that may be instituted against Tottenham or Clene following the announcement of the Merger Agreement and the transactions contemplated therein; (3) the inability to complete the business combination, including due to failure to obtain approval of the shareholders of Tottenham or other conditions to closing in the Merger Agreement; (4) delays in obtaining or the inability to obtain necessary regulatory approvals (including approval from regulators, as applicable) required to complete the transactions contemplated by the Merger Agreement; (5) the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement or could otherwise cause the transaction to fail to close; (6) the inability to obtain or maintain the listing of the post-acquisition company's ordinary shares on NASDAQ following the business combination; (7) the risk that the business combination disrupts current plans and operations as a result of the announcement and consummation of the business combination; (8) the ability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably and retain its key employees; (9) costs related to the business combination; (10) changes in applicable laws or regulations; (11) the possibility that Clene or the combined company may be adversely affected by other economic, business, and/or competitive factors; and (12) other risks and uncertainties to be identified in the Form S-4 filed by Chelsea Worldwide (when available) relating to the business combination, including those under "Risk Factors" therein, and in other filings with the Securities and Exchange Commission (SEC) made by Tottenham and Clene. Tottenham and Clene caution that the foregoing list of factors is neither exclusive nor exhaustive. Tottenham and Clene caution readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Neither Tottenham or Clene undertakes or accepts any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, subject to applicable law. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

Media ContactAndrew MielachLifeSci Communications(646) 876-5868amielach@lifescicomms.com

Investor ContactBruce MackleLifeSci Advisors, LLC(929) 469-3859bmackle@lifesciadvisors.com

Continue reading here:

Clene Nanomedicine Presents Blinded Interim Results from RESCUE-ALS Phase 2 Study at the 31st International Symposium on ALS/MNDResults provide...

$700 Million Worth of Synthetic Bitcoin Is Circulating on the Ethereum Blockchain – Bitcoin News

According to onchain data, theres now 69,836 synthetic bitcoin tokens (over $700 million) circulating on the Ethereum blockchain. Out of the six synthetic bitcoin token projects, wrapped bitcoin (WBTC) commands the largest number of coins with over 63% and 44,622 WBTC.

Synthetic bitcoin (BTC) has grown massively in recent weeks and since news.Bitcoin.coms last report on the subject, there was 38,021 BTC circulating on the Ethereum chain.

Since then, that metric has jumped more than 83% as theres now 69,836 synthetic bitcoin tokens in the wild on September 7, 2020. Dune Analytics shows there are seven synthetic BTC projects but tBTC has zero coins minted, while the other six projects have between 45 BTC to over 40,000.

The top project minting the most synthetic BTC is the Wrapped Bitcoin (WBTC) protocol which commands roughly 44,622 BTC to-date or 63%. The Ren Protocols renBTC has over 23% of the aggregate total of synthetic BTC with 16,268 renBTC in circulation today.

The token hBTC has 4,810 and sBTC has a total of 2,918 at the time of publication. The two projects with the least amount of synthetic BTC is imBTC (1,173) and pBTC (45).

WBTC has gained a lot of traction, and on Monday reports detail that the organization Alameda Research obtained 70% of the WBTC minted in August. Alameda was cofounded by the FTX CEO Sam Bankman-Fried.

A great percentage of synthetic bitcoin is circulating among holders while the rest is used on platforms such as Compound, Balancer, Aave, and Uniswap.

Synthetic bitcoin trades take place on a few centralized exchanges like FTX and Binance has revealed listing WBTC this week. On decentralized exchange (dex) platforms, Synthetic bitcoin trades are happening on 0x, Bancor, Synthetix, Balance, Curve, and Uniswap.

Despite the massive growth and popularity, Ethereum cofounder Vitalik Buterin detailed that he has concerns about synthetic bitcoin projects.

I continue to be worried about the fact that these wrapped BTC bridges are trusted, Buterin wrote on August 16. I hope they can all *at least* move to a decently sized multi-sig, the developer added.

Following Buterins statements, the community discussed a research paper by the Wanchain project which claimed the Ren Protocol kept all the collateralized bitcoin in one address.

Paradoxically, we found that the Bitcoin address provided by renBTC that users transfer their real BTC to for locking has not changed since the first day it went online, the Wanchain report wrote.

Despite the trust issues, with 69,836 synthetic bitcoin tokens on the Ethereum blockchain, the ETH network continues to solidify itself as BTCs most dominant offchain solution.

What do you think about the $700 million worth of BTC circulating on the ETH chain in synthetic form? Let us know in the comments below.

Image Credits: Shutterstock, Pixabay, Wiki Commons, Dune Analytics,

Disclaimer: This article is for informational purposes only. It is not a direct offer or solicitation of an offer to buy or sell, or a recommendation or endorsement of any products, services, or companies. Bitcoin.com does not provide investment, tax, legal, or accounting advice. Neither the company nor the author is responsible, directly or indirectly, for any damage or loss caused or alleged to be caused by or in connection with the use of or reliance on any content, goods or services mentioned in this article.

Read the original here:

$700 Million Worth of Synthetic Bitcoin Is Circulating on the Ethereum Blockchain - Bitcoin News

Exclusive mining could have negative implications for the Blockchain industry, say experts – Cointelegraph

Dr. Elias Strehle of the Blockchain Research Lab and Lennar Ante of the University of Hamburg recently warned that blockchain nodes engaging in exclusive mining have no incentive to forward new transactions to their peers.

They speculated that crypto miners may instead be incentivized to keep transactions confidential in the hope of being the only one who can earn the associated transaction fees.

Exclusive mining, which is a type of collusion between a transaction initiator and a single miner or pool, uses private channels to confirm transactions rather than broadcasting them on the public blockchain. It is only after they are recorded in a block that public blockchain that users become aware of such transactions.

The authors alleged that, since transaction costs represent regular income for miners, significantly increased transaction costs could be used to launder money by colluding with a miner.

As a result, criminals may see smaller blockchain networks as more suitable vehicles for money laundering or tax evasion via exclusive mining, the researchers noted.

Dr. Strehle and Ante identified two other possible motivations for engaging in exclusive mining: reducing transaction cost volatility and hiding unconfirmed transactions from the network to prevent frontrunning.

In June, Cointelegraph reported on a number of mysterious transactions that have stumped the wider community. Some suggest they could be examples of money laundering, or revenge from a disgruntled exchange employee.

Read more from the original source:

Exclusive mining could have negative implications for the Blockchain industry, say experts - Cointelegraph

Reimagining blockchain for healthcare solutions with the MAXathon – Health Europa

Blockchain technology company Maxonrow is hosting its first ever hackathon to help reimagine blockchain for applications in healthcare in response to the global challenges posed by the COVID-19 pandemic.

The MAXathon challenges are based on the Maxonrow SDK script, which the company used to build MedsLOCK. Created in tandem with Avantas Tech Accelerator, MedsLOCK is a blockchain-based control and communication ecosystem that provides real-time insights during pandemics.

During the COVID-19 outbreak, data is crucial to making informed decisions. At the same time, citizens are concerned about any incursion to privacy resulting from data collection initiatives.The MedsLOCK platform provides a single source of reliable, verifiable pandemic analytics to government agencies, health officials, and other stakeholders, and the core objective is to make COVID-19 data collection and exchange between stakeholders automated, transparent, and trusted with the help of distributed ledger technology.

Muhammad Salman Anjum, Avantas Managing Director, said: Privacy is a key issue during the current and future pandemics, and as such, blockchain platforms ensure that information is shared without compromising privacy. With MedsLOCK, we make sure we add trust to the data flow.

Participants in the MAXathon hackathon will have a chance to win a share of a 15,000 prize pool by building solutions for any of the five challenge categories.

The challenges categories are:

Physical Distancing Distancing measures are one of the most impactful ways to contain the spread of COVID-19. How can we use analytics in smarter solutions to help governments implement social or physical distancing measures?

Credential and Certificate Issuance Governments need a way of easily verifying if a patient has had COVID-19 and is virus-free. Help us build a solution that can help governments quickly retrieve verifiable data.

Welfare Businesses and citizens have become reliant on governments for welfare due to the restrictions imposed by the pandemic. Can we lower transaction costs by removing intermediaries and increasing transparency to welfare beneficiaries?

Virtualising the New Normal Are there any creative ways that blockchain can be used to navigate the need for physical distancing, creating new virtual paths to connect with one another?

UI/UX There are many data representations of the pandemic. How can we present a holistic, multi-dimensional dashboard with unique features?

Maxonrow has assembled a stellar team of judges and mentors for MAXathon, including Holger Schmidt, partner at PwCs strategy division, Nisa Amoils of VC firm Grasshopper Capital, along with representatives from Audi, Dash.org, and members of Maxonrow and Avantas Techs senior leadership.

There will also be 16 mentors working with participating teams, comprised of members of Maxonrows technical teams and leaders within the blockchain space.

The latter includes Amber Urquhart, Head of Business Development at quant trading firm TDX Strategies, Gabriel Dymowski, CEO at Doxychain, and a laureate of Forbes 25 under 25. Also participating in the mentorship team are Massimo Buoni, a UN global technology expert, and Steven Boylan, co-founder and CEO of Trt:Labs, a specialist digital transformation consultancy.


Reimagining blockchain for healthcare solutions with the MAXathon - Health Europa